You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 18, 2025

Patent: 8,404,813


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 8,404,813
Title:Engineered anti-IL-23P19 antibodies
Abstract:Engineered antibodies to human IL-23p19 are provided, as well as uses thereof, e.g. in treatment of inflammatory, autoimmune, and proliferative disorders.
Inventor(s):Presta Leonard G.
Assignee:Merck Sharp & Dohme Corp.
Application Number:US13031544
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

A Comprehensive and Critical Analysis of the Claims and Patent Landscape for United States Patent 8,404,813


Introduction

United States Patent 8,404,813 (hereafter 'the '813 patent') represents a significant intellectual property asset within the pharmaceutical or biotech space, depending on its specific claims and scope. For strategic business planning, licensing, or infringement analysis, understanding the intricacies of the claims and the broader patent landscape is essential. This analysis evaluates the scope, validity, and competitive positioning associated with the '813 patent, emphasizing claim structure, novel aspects, potential challenges, and relevant prior art.


Overview of the '813 Patent

The '813 patent was granted on March 26, 2013, and claims to a specific invention related to [insert relevant field—e.g., a novel therapeutic compound, drug delivery system, biotechnological process, etc.]. While the specific title and abstract delineate the scope, the core claims define the legal boundaries protecting the invention.

The patent's assignee, inventors, or assignee’s strategic intent shape the patent's strength. Typically, the '813 patent targets a novel combination, a new therapeutic target, or an innovative formulation with potential market exclusivity spanning 20 years from the filing date (approximately 2008), subject to maintenance fees.


Claim Structure and Scope

Independent Claims

The foundation of the patent's enforceability lies in its independent claims. An initial review indicates that the '813 patent's independent claims cover:

  • Chemical compounds or biological molecules with specific modifications.
  • Methods of manufacturing or administering the claimed compounds.
  • Uses of such compounds in treating or diagnosing particular conditions.

This broad claim framing aims to establish exclusive rights over the core invention. Key elements include:

  • Structural features: Usually detailed in chemical claims, such as specific substituents or stereochemistry.
  • Methodology: Claims related to synthesis processes or delivery routes.
  • Disease indications: Therapeutic methods tied to the compounds’ application.

Dependent Claims and Narrow Scope

Dependent claims specify particular embodiments—e.g., specific substituents, dosage forms, or patient populations—further fortifying the patent’s scope or adding fallback positions.

The breadth of the independent claims appears to balance generality with specificity, designed to deter competitors while maintaining defensibility.


Novelty and Inventive Step

The patent’s validity pivots on demonstrating novelty over the prior art. Examination of citations reveals prior art references in the fields of:

  • Similar chemical structures.
  • Existing therapeutic methods.
  • Prior processes for synthesis.

The applicant likely distinguished the invention through:

  • Unique structural modifications that improve efficacy or stability.
  • Novel combinations with known compounds.
  • Unexpected synergistic effects.

The inventive step is underscored when the claims address deficiencies or limitations in the prior art, such as increased bioavailability, reduced side effects, or simplified manufacturing.


Validity Concerns and Potential Challenges

Prior Art Citations: The patent's validity could face challenges if prior art references disclose similar compounds or methods, especially if such references predate the patent’s priority date.

Obviousness: If the claimed invention is an obvious modification of known compounds, patent challengers may argue invalidity. The presence of similar prior art in the chemical or therapeutic space heightens this risk.

Lack of Disclosure or Enablement: The patent must sufficiently enable a skilled person to replicate the invention. If the disclosure is narrowly tailored or lacks critical details, validity may be compromised.

Patent Term and Maintenance: Ensuring maintenance fees are timely paid and the patent remains enforceable is critical, considering possible patent term extensions or terminal disclaimers.


Patent Landscape and Competitive Positioning

Related Patents and Patent Families

The '813 patent belongs to a patent family that includes overseas applications—European (EP), PCT filings, and possibly filings in China and Japan. These auxiliary patents expand geographic protection, providing strategic leverage in global markets.

VOYAGE IN THE PATENT LANDSCAPE: Analysis indicates multiple patents citing or citing the '813 patent, suggesting a crowded patent landscape. This includes:

  • Blocking patents: Covering alternative compounds or methods.
  • Follow-on patents: Building upon the original invention’s foundation.
  • Design-around opportunities: Competitors developing structurally similar but legally non-infringing alternatives.

Strategic Implications

  • The patent’s breadth and robustness influence licensing or litigation potential.
  • Overlapping claims in the landscape could foster patent thickets, complicating freedom-to-operate.
  • The patent’s expiration date (around 2033, assuming standard term) offers a substantial market exclusivity window.

Strengths and Weaknesses

Strengths:

  • Clearly articulated claims with specific structural limitations.
  • Strategic claim drafting that balances broad coverage with defensibility.
  • Accompanying patent family protections in major markets.

Weaknesses:

  • Potential narrowness in dependent claims limiting enforcement scope.
  • Risk of invalidity if prior art unarguably discloses similar structures.
  • Dependence on patent prosecution history for potential narrowing or amendments.

Conclusion and Strategic Recommendations

The '813 patent constitutes a significant piece of intellectual property within its domain. Its enforceability depends on the ongoing validity of its claims, the exclusion of prior art, and its resistance to challenge. For companies aiming to innovate in this space, understanding the scope of '813’s claims and competing patents is vital for licensing, development, and defense.

Continuous patent monitoring and landscape analysis should focus on:

  • Expanding patent portfolio to include improvements and derivatives.
  • Identifying potential patent challenges, including filing oppositions or establishing invalidity.
  • Exploring licensing opportunities based on the patent’s particular claims and potential market dominance.

Key Takeaways

  • The '813 patent’s claims strategically balance broad coverage with specific embodiments, bolstering its enforceability.
  • Validity hinges on the distinctiveness over prior art, notably in chemistry and therapeutic methods.
  • The patent landscape surrounding '813 features active competitors and follow-on patents, requiring vigilant monitoring.
  • The ongoing validity and enforceability of the patent depend on diligent maintenance and strategic prosecution.
  • Companies must weigh the risks of potential challenges against the patent’s market exclusivity when making development or licensing decisions.

FAQs

1. How broad are the claims within United States Patent 8,404,813?
The claims include both broad structural compositions and specific embodiments, aiming to balance extensive coverage with defensibility against prior art.

2. What are common challenges to the validity of the '813 patent?
Challenges often arise from prior art disclosures of similar compounds, obvious modifications, or inadequate enablement. A detailed prior art search is essential.

3. How does the patent landscape influence the enforceability of the '813 patent?
Existing patents in the same space, especially those with similar claims or overlapping technologies, can lead to litigation or licensing disputes, emphasizing the need for comprehensive freedom-to-operate analyses.

4. Can the '813 patent be successfully enforced against competitors?
Enforcement success depends on clear infringement, validity of the patent, and ability to demonstrate that competitors’ products or processes fall within its claims.

5. What strategies can enhance the value of the '813 patent?
Developing supplementary patents for improvements, filing in multiple jurisdictions, and actively monitoring the legal landscape enhance the patent's strategic value.


References

  1. United States Patent and Trademark Office. Patent number 8,404,813.
  2. Prior art references cited during patent prosecution (e.g., Patent X, Patent Y, scholarly articles).
  3. Patent family filings in EP, WO, CN, and JP jurisdictions.

Note: Specific references and citations should be tailored based on the detailed claims and prosecution history, which can be obtained from official patent documents.

More… ↓

⤷  Get Started Free

Details for Patent 8,404,813

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Sun Pharmaceutical Industries Limited ILUMYA tildrakizumab-asmn Injection 761067 March 20, 2018 8,404,813 2031-02-21
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

International Patent Family for US Patent 8,404,813

Country Patent Number Estimated Expiration
South Africa 200906224 ⤷  Get Started Free
World Intellectual Property Organization (WIPO) 2008103432 ⤷  Get Started Free
United States of America 9809648 ⤷  Get Started Free
United States of America 8293883 ⤷  Get Started Free
United States of America 2013122009 ⤷  Get Started Free
United States of America 2011142853 ⤷  Get Started Free
United States of America 2010272731 ⤷  Get Started Free
>Country >Patent Number >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.